In this article, European Pharmaceutical Review’s Hannah Balfour explores some of big pharma’s latest developments in HIV treatment, with commentary from ViiV Healthcare’s Head of Research and Development, Kimberly Smith.
List view / Grid view
EPR's Victoria Rees interviews Dr Jaime Oliver Vigueras from Janssen to discuss rilpivirine, Janssen's long acting monthly injectable HIV treatment.
A new report has predicted that the global antibiotics market will grow at a CAGR of four percent from 2020-2027.
Alzheimer’s and diabetes enter the top ten global causes of death for the first time, while HIV/AIDS and tuberculosis deaths fall, according to the WHO’s 2019 Global Health Estimates.
A clinical trial in the UK has shown that lopinavir-ritonavir is not an effective treatment for patients admitted to hospital with COVID-19.
Adherence to medicines – ie, maintaining consistency and complying with correct dosage – is vital for treatment success, yet patient non-adherence remains a global concern, risking a multitude of consequences for both the patients and healthcare systems. Dave Elder explores the issue of medicine adherence and expounds on current efforts…
Despite some positive results from clinical trials for COVID-19 treatments, separate tests of the same therapies have not met primary endpoints.